Search

Displaying results 2571 - 2580 of 10000 in total
  1. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  2. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. … Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required for viral protein production.

    Mixtures: HARVONI 90 MG/400 MG FILM KAPLI TABLET, 84 ADET, HARVONI 90 MG/400 MG FILM KAPLI TABLET, 28 ADET
  3. Drug

    Tenofovir

    go.drugbank.com/drugs/DB14126
    Investigational

    [A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order … [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.

    Mixtures: EMTRICITABINA 200 MG TENOFOVIR 300 MG, EMTRICITABINA 200 MG TENOFOVIR 300 MG
  4. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052,L64053] It is the second fluorine-18 tau PET imaging agent approved in the United States, after flortaucipir (Tauvid), which was approved in 2020.[L64054,L14114] … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease

  5. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    [A35677] It was FDA approved on July 20, 2018.[L3770] … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.

  6. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  7. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    levels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue. … [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues.

  8. Drug

    Mannitol busulfan

    go.drugbank.com/drugs/DB12097
    ApprovedWithdrawn

    Mm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.

  9. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

  10. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected